Tilray Medical strengthened its position in Europe with marketing authorization in Poland. The Canadian company has received approval to market its medical cannabis products in the country, expanding its product offering and distribution in pharmacies across Europe.
Denise Faltischek, Director of Strategy and Head of International Affairs at Tilray, said, “I am extremely proud of our team in Europe for once again extending our authorization for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable, high-quality medical cannabis in Europe and countries around the world. »
In Poland, the company has established multiple partnerships with pharmaceutical companies to distribute branded and unbranded medical cannabis products. Patients can obtain prescriptions for medical cannabis in Poland through their GP.
The company said its products have been “selected to ensure patients receive the highest product quality and consistency in the supply of their medical cannabis products.”
Earlier this year, Tilray announced that it was merging its medical division, which includes that of Aphria, under the common banner of Tilray Medical, uniting the company’s medical cannabis brands under a single strategy, mission and vision. .
The company also announced that its medicines are now available in Malta on prescription in pharmacies on the island and since 2021 in Luxembourg.
Last month, Tilray Medical’s parent company, Tilray Brands, announced record results for fiscal year 2022, with net income of $628 million, a 22% increase over the previous year.
